comparemela.com

Latest Breaking News On - Proximal complement inhibitor - Page 1 : comparemela.com

Novartis Pharma AG: Novartis presents pivotal Phase III APPLY-PNH data at ASH demonstrating investigational oral monotherapy iptacopan superiority over anti-C5

Trial met both primary and most secondary endpoints, showing iptacopan provided transfusion-free hemoglobin-level increases in vast majority of adult paroxysmal nocturnal hemoglobinuria (PNH) patients

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.